Vanguard Personalized Indexing Management LLC Decreases Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Vanguard Personalized Indexing Management LLC trimmed its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,755 shares of the company’s stock after selling 232 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Prestige Consumer Healthcare were worth $251,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PBH. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the second quarter worth about $26,000. Quest Partners LLC increased its position in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Prestige Consumer Healthcare during the second quarter worth about $35,000. Finally, ORG Partners LLC acquired a new stake in Prestige Consumer Healthcare during the second quarter worth about $39,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PBH shares. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock opened at $71.32 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. The stock has a market capitalization of $3.53 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 2.01 and a beta of 0.48. The business has a 50-day moving average of $71.21 and a 200 day moving average of $69.60. Prestige Consumer Healthcare Inc. has a 12 month low of $56.34 and a 12 month high of $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. The firm had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 earnings per share. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.